These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27118534)

  • 1. No increased heart failure risk is reported with DPP-4 inhibitors.
    Wise J
    BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
    BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
    Patel T; Tesfaldet B; Gandotra C;
    BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
    Sano M
    J Cardiol; 2019 Jan; 73(1):28-32. PubMed ID: 30318179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 6. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk.
    Vaduganathan M; Singh A; Sharma A; Januzzi JL; Scirica BM; Butler J; Zannad F; McGuire DK; Cannon CP; Bhatt DL
    Am J Cardiol; 2020 May; 125(10):1577-1581. PubMed ID: 32245636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worsening Heart Failure During the Use of DPP-4 Inhibitors: Pathophysiological Mechanisms, Clinical Risks, and Potential Influence of Concomitant Antidiabetic Medications.
    Packer M
    JACC Heart Fail; 2018 Jun; 6(6):445-451. PubMed ID: 29525332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart failure and dipeptidyl peptidase-4 inhibitors.
    Krum H; Skiba M; Wu S; Hopper I
    Eur J Heart Fail; 2014 Jun; 16(6):603-7. PubMed ID: 24687300
    [No Abstract]   [Full Text] [Related]  

  • 9. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
    Gallwitz B
    Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038
    [No Abstract]   [Full Text] [Related]  

  • 10. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
    Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials.
    Kappel BA; Marx N; Federici M
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):697-705. PubMed ID: 26164634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
    Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
    J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
    Hassanabad MF; Hassanabad AF; Fatehi M
    Curr Diabetes Rev; 2022; 18(8):e161221199093. PubMed ID: 34915838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent safety updates on type 2 diabetes medications: a case report and the evidence for choosing among several available drugs for this patient.
    Sisson EM; Mills J; Chin L
    Am J Nurs; 2012 Dec; 112(12):49-53. PubMed ID: 23190674
    [No Abstract]   [Full Text] [Related]  

  • 17. Dipeptidyl peptidase-iV inhibitors: fixing type 2 diabetes?
    McIntyre HF; Grant P
    Br J Hosp Med (Lond); 2007 Nov; 68(11):599-602. PubMed ID: 18087847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Kundu A; Sardar P; Ghosh S; Patel P; Chatterjee S; Meyer TE
    Int J Cardiol; 2016 Jun; 212():203-5. PubMed ID: 27043061
    [No Abstract]   [Full Text] [Related]  

  • 19. Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study.
    Giorda CB; Picariello R; Tartaglino B; Marafetti L; Di Noi F; Alessiato A; Costa G; Gnavi R
    BMJ Open; 2015 Jun; 5(6):e007959. PubMed ID: 26048211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.